Evidence map›Paper›PMID 25358339›Full record

ArticleNephron. Physiology2014

Insulin Receptor and the Kidney: Nephrocalcinosis in Patients with Recessive INSR Mutations.

Arabella Simpkin, Elaine Cochran, Fergus Cameron, Mehul Dattani, Martin de Bock, David B Dunger, Gun Forsander, Tulay Guran, Julie Harris, Iona Isaac and 10 more

Open access · hybridAbstract read
In one paragraph

Article in Nephron. Physiology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. One Novel 2.43Kb Deletion and One Single Nucleotide Mutation of theJournal of clinical research in pediatric endocrinology · 2018
    Article
  6. Review
  7. Article
  8. Article
  9. What is nephrocalcinosis?Kidney international · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 14 institutions in 9 countries.

Arabella Simpkin
Elaine Cochran
Fergus Cameron
Mehul Dattani
Martin de Bock
David B Dunger
Gun Forsander
Tulay Guran
Julie Harris
Iona Isaac
Khalid Hussain
Robert Kleta
Catherine Peters
Velibor Tasic
Rachel Williams
Fabian Yap Kok Peng
Stephan O''Rahilly
Philipp Gorden
Robert K Semple
Detlef Bockenhauer
Great Ormond Street Hospital for Children NHS Foundation Trust · GBNational Institute for Health Research · GBNational Institute of Diabetes and Digestive and Kidney Diseases · USUniversity College London · GBAddenbrooke's Hospital · GBKK Women's and Children's Hospital · SGMarmara University · TRNIHR Cambridge Biomedical Research CentreRoyal Children's Hospital · AUSahlgrenska University Hospital · SEUniversity Clinic of Traumatology · ATUniversity of Auckland · NZUniversity of Cambridge · GBWellcome/MRC Institute of Metabolic Science · GB

Funding

Molecular and Clinical Studies of Insulin ResistanceZIADK047050 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI BROWN, REBECCA · 2009 to 2025
$6.1M
Department of Health NF-SI-0508-10274Medical Research Council G1001821Medical Research Council MC_UU_12012/5Medical Research Council MC_UU_12012/5/BWellcome Trust 095515Wellcome Trust 098498Wellcome Trust 100574
6 · The paper itself

Abstract

BACKGROUND/

aimsDonohue and Rabson-Mendenhall syndrome are rare autosomal recessive disorders caused by mutations in the insulin receptor gene, INSR. Phenotypic features include extreme insulin resistance, linear growth retardation, paucity of fat and muscle, and soft tissue overgrowth. The insulin receptor is also expressed in the kidney, where animal data suggest it plays a role in glomerular function and blood pressure (BP) regulation, yet such a role in the human kidney is untested. Patients with biallelic INSR mutations provide a rare opportunity to ascertain its role in man.

methodsRetrospective review of patients with INSR mutations. Data for BP, renal imaging, plasma creatinine and electrolyte levels, as well as urine protein, albumin and calcium excretion were sought from the treating clinicians.

resultsFrom 33 patients with INSR mutations, data were available for 17 patients. Plasma creatinine was low (mean ± SD: 25 ± 9 μmol/l) and mean plasma electrolyte concentrations were within the normal range (n = 13). Systolic BP ranged between the 18th and 91st percentile for age, sex, height and weight (n = 9; mean ± SD: 49 ± 24). Twenty-four-hour urinary calcium data were available from 10 patients and revealed hypercalciuria in all (mean ± SD: 0.32 ± 0.17 mmol/kg/day; normal <0.1). Nephrocalcinosis was present in all patients (n = 17). Urinary albumin excretion (n = 7) ranged from 4.3-122.5 μg/min (mean ± SD: 32.4 ± 41.0 μg/min; normal <20).

conclusionsINSR dysfunction is associated with hypercalciuria and nephrocalcinosis. No other consistent abnormality of renal function was noted. Normotension and stable glomerular function with only moderate proteinuria is in contrast to genetically modified mice who have elevated BP and progressive diabetic nephropathy.

Indexed as

Donohue syndromeHypercalciuriaINSRInsulin receptorLeprechaunismNephrocalcinosisRabson-Mendenhall syndrome

Identifiers

PMID25358339
PMCPMC4369119
OpenAlexW1977300685

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.